Genome Research cityscape

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Published online before print June 28, 2007, 10.1101/gr.6468307
Genome Res. 17:1195-1201, 2007
©2007 by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/07 $5.00
OPEN ACCESS ARTICLE
This Article
OPEN ACCESS ARTICLE
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Research Data
Right arrow All Versions of this Article:
gr.6468307v1
17/8/1195    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, C.
Right arrow Articles by Shafer, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, C.
Right arrow Articles by Shafer, R. W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Methods

Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistance

Chunlin Wang1,3, Yumi Mitsuya1,3, Baback Gharizadeh2, Mostafa Ronaghi2, and Robert W. Shafer1,4

1 Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California 94305, USA; 2 Stanford Genome Technology Center, Stanford University, Stanford, California 94305, USA

The detection of mutant spectra within a population of microorganisms is critical for the management of drug-resistant infections. We performed ultra-deep pyrosequencing to detect minor sequence variants in HIV-1 protease and reverse transcriptase (RT) genes from clinical plasma samples. We estimated empirical error rates from four HIV-1 plasmid clones and used them to develop a statistical approach to distinguish authentic minor variants from sequencing errors in eight clinical samples. Ultra-deep pyrosequencing detected an average of 58 variants per sample compared with an average of eight variants per sample detected by conventional direct-PCR dideoxynucleotide sequencing. In the clinical sample with the largest number of minor sequence variants, all 60 variants present in ≥3% of genomes and 20 of 35 variants present in <3% of genomes were confirmed by limiting dilution sequencing. With appropriate analysis, ultra-deep pyrosequencing is a promising method for characterizing genetic diversity and detecting minor yet clinically relevant variants in biological samples with complex genetic populations.


3 These authors contributed equally to this work.

4 Corresponding author.

E-mail rshafer{at}stanford.edu; fax (650) 725-2088.

[Supplemental material is available online at www.genome.org. The raw data from this study are available online at http://dbpartners.stanford.edu/454/pub.]

Article published online before print. Article and publication date are online at http://www.genome.org/cgi/doi/10.1101/gr.6468307


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Genes Dev. Learn. Mem.
Protein Science RNA Genome Res.
Copyright © 2007 by Cold Spring Harbor Laboratory Press.